Exercise program for women with ovarian cancer before surgery
The Impact of Prehabilitation Exercise on Frailty and Treatment Outcomes in Ovarian Cancer Patients
This study tests whether a structured exercise program can help women with advanced ovarian cancer get stronger and recover better before their surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 108 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Nova Scotia Health Authority Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Halifax, Nova Scotia) |
| Trial ID | NCT05364879 on ClinicalTrials.gov |
What this trial studies
This study focuses on prehabilitation for women diagnosed with stage III or IV ovarian cancer, aiming to improve their physical condition before undergoing cytoreductive surgery. The intervention involves a structured exercise program designed to address frailty, which is common among these patients and can negatively impact surgical outcomes. Participants will engage in in-person and/or virtual exercise sessions, with a minimum of four weeks between enrollment and surgery to allow for adequate preparation. The goal is to enhance recovery and reduce complications associated with surgery.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 or older with a confirmed diagnosis of stage III or IV ovarian cancer who are scheduled for cytoreductive surgery.
Not a fit: Patients who have already undergone surgery or have significant health issues that prevent safe participation in exercise will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved surgical outcomes and recovery for women with ovarian cancer.
How similar studies have performed: While the specific approach of prehabilitation for ovarian cancer is novel, similar interventions in other cancer types have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * Have a confirmed diagnosis of stage III or IV ovarian cancer * Scheduled to receive cytoreductive surgery as part of their treatment plan * Must have a minimum of 4-weeks between the time of study enrollment and scheduled surgery * Be able to attend in-person and/or virtual exercise sessions * Be fluent in English * Have oncologist approval Exclusion Criteria: * Have already completed surgery * Unstable cardiac or respiratory disease, injury or any other co-morbid disease that may make it unsafe for participants to exercise * Significant cognitive impairment (e.g., do not have the capacity to consent, unable to follow exercise instructions)
Where this trial is running
Halifax, Nova Scotia
- Nova Scotia Health — Halifax, Nova Scotia, Canada (Recruiting)
Study contacts
- Principal investigator: Scott Grandy, PhD — Nova Scotia Health
- Study coordinator: Scott Grandy, PhD
- Email: grandy@dal.ca
- Phone: 902-494-1145
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.